ALK Positive's Research Priorities - April 21, 2024 ALKtALK

ALK Positive Inc (API) has a sense of urgency that drives our work toward the discovery and deployment of even better, and ultimately curative, treatments for ALK-positive cancer. Watch this ALKtALK to hear our own Drs Ken Culver and Marc Muskavitch highlight how API is advocating with industry and medical professionals to prioritize ALK research. Ken and Marc also discuss the initiatives we’re backing with our valuable research dollars to accelerate research and bring new treatment opportunities to ALK-positive cancer patients. Not to be missed.

[@garettmarshall1519]

Excellent update and information! Thank you

[@vwood751]

Great presentation. Interesting to learn about MRD and ALK+ focus on this.

[@periwinkycrafts]

Fantastic overview. I love it and hope to support leveraging AI for change detection, and identification of potential oligoprogression.

[@YoungLungCancer]

Yes!! Great for our patient population !!

[@angeladibra7496]

Great job, you are the best 😊

[@laurenlongworth4584]

It makes me so proud to be part of this group. Ken has a way of describing things so they are clearly understandable but not too dumbed down for us laypeople.

[@user-pv2qd5jn3l]

For Alk positive is match with car T cell therapy or immunotherapy ?

[@user-pv2qd5jn3l]

Too much study and investigation drive crazy,